Tufts Medical Center
Pathology residency · Boston, MA · Tufts Medical Center programs · Program website
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Tufts Medical Center's research in pathology, which the program shares with other departments and affiliated hospitals.
Pathology at Tufts Medical Centershared by every program there, not this program's own
Institution-level: all pathology publications from Tufts Medical Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
Works per year · * 2026 so far
Pathology research topics at Tufts Medical Center
Papers in the window; each links to the list on OpenAlex.
Most cited at Tufts Medical Center since 2024
All pathology papers there on OpenAlex
- Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trialHishan Tharmaseelan et al. · HemaSphere · 2026 · PubMed · cited 1
- Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M. Castellino et al. · Journal of Clinical Oncology · 2026 · PubMed · cited 9
- Comparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331Bradford S. Hoppe et al. · International Journal of Radiation Oncology*Biology*Physics · 2025 · PubMed · cited 10
- An Individualized Prediction Model for Early-Stage Classic Hodgkin’s LymphomaAngie Mae Rodday et al. · NEJM Evidence · 2025 · PubMed · cited 6
- Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C. Rutherford et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 36
- Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trialWon Seog Kim et al. · Nature Cancer · 2025 · PubMed · cited 61
- The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online toolMatthew John Maurer et al. · Blood Advances · 2025 · PubMed · cited 7
- Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin LymphomaRasmus Rask Kragh Jørgensen et al. · JCO Clinical Cancer Informatics · 2024 · PubMed · cited 14
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali et al. · Blood Advances · 2024 · PubMed · cited 8
- Harnessing multi-source data for individualized care in Hodgkin LymphomaSusan Kenyon Parsons et al. · Blood Reviews · 2024 · PubMed · cited 4
Add to your program's websitea badge, your paper list, a feed
For program directors and coordinators. Both update with the site and need no account.
<a href="https://openprograms.org/programs/tufts-medical-center-path"><img src="https://openprograms.org/programs/tufts-medical-center-path/badge.svg" alt="Tufts Medical Center Pathology residency on OpenPrograms" height="20"></a>Something wrong or missing on this page? Use the correction form below; changes show up in both.